1 / 65

HIV-Related Oral Manifestations in Women: A Comprehensive Review

Explore epidemiology, types, clinical presentation, and treatment of oral lesions in HIV-infected women, including candidiasis, hairy leukoplakia, HPV lesions, and Kaposi’s sarcoma. Understand prevalence changes and care approaches.

messick
Download Presentation

HIV-Related Oral Manifestations in Women: A Comprehensive Review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ORAL HEALTH IN WOMENORAL MANIFESTATIONS OF HIV INFECTION dr shabeel pn

  2. DENTAL HEALTH CARE PROVIDER TEAM APPROACH

  3. EPIDEMIOLOGY OF HIV-RELATED ORAL MANIFESTATIONS IN WOMEN

  4. Epidemiology of HIV-Related Oral Manifestations in Women: A Review • Oral Lesions in 15% of HIV-Infected Women • Most Common Oral Lesion - Candidiasis • Prevalence of Hairy Leukoplakia and Kaposi's Sarcoma Significantly Less Common in Women Oral Dis1997 Sep;3(3):206.

  5. Many Manifestations of HIV Disease are Similar in Men & Women • Other Conditions Differ In Frequency: • HIV-Infected Men 8 X’s More Likely to Develop Kaposi's Sarcoma • Women Have Higher Rates of Esophageal Candidiasis & Herpes Simplex Infections

  6. CHANGINGPREVALENCE OF ORAL MANIFESATIONS

  7. Overall Prevalence of Oral Lesions Has Decreased (47.6%-37.5%) • Hairy Leukoplakia (25.8%-11.4%) & Necrotizing Periodontal Diseases (4.8%-1.7%) Decreased

  8. HIV Salivary Gland Disease Increased (1.8%-5.0%) • Candidiasis (20.3%-16.7%), Aphthae (3.7%-3.0%), Oral Warts (2.2%-4.0%), Herpes Simplex Virus Lesions (1.8%-2.0%) and Kaposi’s Sarcoma (1.1%-0.3%) Unchanged

  9. HIV/AIDS Women's Health: Oral Lesions in HIV-Positive Women Reduced in HAART Therapy • 503 HIV+ women over 6 years • Incidence of EC fell to 2.99 percent from 5.48 percent • PC fell to 2.85 percent from 6.70 percent • No changes were seen in HL or warts Women's Health Weekly (03.25.04)

  10. CANDIDIASIS

  11. Reported in 7-93% of HIV+ /AIDS Patients

  12. FOUR MAJOR TYPES • Pseudomembranous • Hyperplastic • Erythematous (Atrophic) • Angular Cheilitis

  13. PSEUDOMEMBRANOUS • White or Yellow Patches • Easily Removed w/ Scraping Yielding Bleeding Surface • Any Mucosal Surface (Palate, Buccal or Labial Mucosa, Tongue)

  14. HYPERPLASTIC CANDIDIASIS • White Plaques Can’t Be Removed w/ Scraping • Buccal Mucosa Most Common Site in HIV+ Patients

  15. ERYTHEMATOUS (ATROPHIC) • Fiery Red Surfaces to Hardly Discernible Pink Spots • Most Common Location - Palate & Dorsum of Tongue • Spotty Areas in Buccal Mucosa

  16. ANGULAR CHEILITIS • Common in Elderly • Fissures Radiating From Angles of Mouth

  17. PREDISPOSING FACTORS

  18. SYSTEMIC FACTORS • Age • Use of Antibiotics • Xerostomia • Nutritional Deficiencies • Immunosuppression • Gastric Reflux

  19. LOCAL FACTORS • Ill-Fitting Dentures • Poor Prosthesis Hygiene • Heavy Smoking • Topical Medications

  20. CANDIDIASIS TREATMENT • Nystatin Oral Susp • 480 ml • Rinse w/ One Tablespoonful QID • Clotrimazole (Mycelex) Troches • 10 mg Troches • 3-5 Times a Day for 7-14 Days

  21. Ketoconazole (Nizoral) • 200 mg • 200-400 mg Daily for 7-14 Days • Fluconazole (Diflucan) • 100 mg Tabs • 2 Tabs First Day, Then 1 Tab Daily for 14 Days • Itraconazole (Sporanox) • 100 mg Tablets • 1 tablet B.I.D. for 14 days

  22. OROFACIAL VIRAL INFECTIONS IN IMMUNOCOMPROMISED HOST

  23. HAIRY LEUKOPLAKIA • First Identified Among HIV+ Individuals • Never Described Before AIDS Epidemic

  24. CLINICAL PRESENTATION • Painless White Patches • Do Not Rub Off • Lateral Borders of the Tongue • Surface May Be Smooth, Corrugated or Markedly Folded • Thick, Hair-Like Projections

  25. DIFFERENTIAL DIAGNOSIS • Hyperplastic Candidiasis • Geographic Tongue • Lichen Planus • Frictional Keratosis • Leukoplakia

  26. HAIRY LEUKOPLAKIA - PATHOGENESIS • Epstein-Barr Virus

  27. HAIRY LEUKOPLAKIA TREATMENT • Appears to Be Little Advantage in Treating • Surgical Removal • Laser • Acyclovir • Topical Vitamin A

  28. HUMAN PAPILLOMA VIRUS LESIONS

  29. HUMAN PAPILLOMA VIRUSES • More Than 100 Human Papilloma Virus (HPV) Types • 24 Associated with Oral Lesions

  30. HPV ORAL LESIONS • Warts, Papillomas • Condyloma Acuminatum • Verruca Vulgaris • Focal Epithelial Hyperplasia • Dysplasia / Carcinoma

  31. HUMAN PAPILLOMA VIRUS LESIONS

  32. CONDYLOMA ACUMINATUM • Sexually Transmitted • Appears 1-3 Months After Exposure • Multiple Wart-Like Lesions • Lips, Lingual Frenum & Tongue

  33. TREATMENTCONDYLOMA ACUMINATUM • Surgical Removal • Cryotherapy • Laser Therapy • Medications

  34. KAPOSI’S SARCOMA

  35. Originally Described in 1872 - Idiopathic Multiple Sarcomas of the Skin

  36. Previously Uncommon in USA • Elderly Jewish Men of Eastern European or Mediterranean Descent • Usually Involved Lower Extremities • Indolent Course • 1981 - Fulminant, Aggressive Form Occurring in Young Homosexual Men w/ AIDS

  37. >50% of AIDS Patients w/ KS Display Oral Lesions • Remains Significant Cause of Morbidity & Mortality in HIV Infected Patients

  38. CLINICAL PRESENTATION • Angiomatous Malignancy of Skin, Mucosa, and Internal Organs • Most Common Intraoral Locations • Palate • Gingiva • Non-Elevated Macules, Nodules or Papules • Brown, Blue, Purple

  39. KAPOSI’S SARCOMAPATHOGENESIS Sexually Transmitted Cofactor Human Herpes Virus 8 (HHV 8)

  40. TREATMENT • Treatment Reserved for Lesions Which Interfere w/ Function or Esthetics • Laser Excision • Cryotherapy • Radiation • Intralesional Injection w/ Vinblastine

  41. CANCER IN PATIENTS WITH AIDS

  42. AIDS AND CANCER • Roche et al, NJ Med2001,Jan;98(1);27-36 • 2460 Persons w/ AIDS and Cancer • 2159 Males, 301 Females • 50% Kaposi’s Sarcoma • 33% Non-Hodgkins Lymphoma • Lung, Oral, Cervical, Hodgkins Lymphoma, Other Digestive

  43. RECURRENT ORAL ULCERATIONS

  44. RECURRENT APHTHOUS STOMATITIS

  45. EPIDEMIOLOGY • Prevalence in General Population 10-20% • 67-85% Develop Prior to Age 30 • Familial Disposition

  46. MINOR APHTHAE • Superficial Erosion with Fibrinous Coating & Red Halo • Single or Multiple Lesions • 2-3 mm’s to Over 10 mm’s in Diameter • Persists for 7-10 Days • Painful

  47. MAJOR APHTHAE • Large Painful Ulcerations • Single or Multiple Lesions • Persists Up to 6 Weeks • Heal w/ Scarring

  48. GENERAL RULE • Aphthae Occur on Mobile Mucosa • Herpetic Lesions Occur on Tissue That is Firmly Bound Down

  49. FACTORS ASSOCIATED WITH APHTHAE • Psychological (Stress) Trauma • Socio-Economic S. sanguis • Endocrine • Immunosuppression • Hereditary • Hypersensitivity • Chemicals in Food

  50. TREATMENT • Chlorhexidine • Topical Steroids • Lidex Gel .05% • Aphthasol Cream 5%

More Related